Colorectal Cancer
Conditions
Keywords
patients, medium risk, asymptomatic, between 50 and 74 years old, high risk, case, history of neoplastic colic, cancers, polyps
Brief summary
Colorectal cancer is one of the most frequent and it prognosis is still serious. In France, diagnosis and screening applicated in numerous departements, and now in a path of generalization to the all country, is based on combination of searching blood into bowel movements (Haemoccult) for the screening of population with medium risk (age between 50 to 74 years old)and colonoscopy for the screening and diagnosis of pre-cancerous lesions for the patients with a high risk.Even if the efficiency of this strategy is proved, searching blood into the bowel movement by Haemoccult is still imperfect (a lot of false negative). Colonoscopy is not an ideal tool for screening. Indeed, its acceptability is not perfect and it constitute an invasive method, with complications, with a compulsory general anesthesia, implicating a high cost. The alternative of a screening method based on a non invasive method is required.
Interventions
4l of PEG during 2 days
2x 10mg Motilium, 2 Fleet Phospho soda (one is facultative) and 1 dulcolax (facultative)
1l of PEG the morning just before colonoscopy
Sponsors
Study design
Eligibility
Inclusion criteria
* age between 18 and 80 years * patient able to give his informed consent * No colorectal, intestinal inflammatory, ischemic or evolving infectious pathologies * No signs of stenosis of small intestine or colon * No contraindication to anesthesia * No participation to an other clinical study * Patient with and indication to colonoscopy for searching of a colorectal neoplasia during a screening program OR * Patient for who a endoscopic following is required because of familial cases or personal cases of polyps or colorectal cancer
Exclusion criteria
* Presence of symptoms evocating an occlusive pathology * Recent complicated colic diverticulosis * No informed consent * pregnancy or no use of efficient contraception treatment * Patient with a pace-maker or others internal medical electronic device * Evolved nephric or cardiac insufficiencies * Hypersensibility to Fleet Phospho Soda (or one of the excipient), bisacodyl (or one of the excipient), motilium (or one of the excipient) * Presence of a prolactinoma
Countries
France